• Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin's lymphoma.

Topoisomerase IIalpha expression as an independent prognostic factor in Hodgkin's lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research (2008-03-19)
Ipatia A Doussis-Anagnostopoulou, Theodoros P Vassilakopoulos, Irini Thymara, Penelope Korkolopoulou, Maria K Angelopoulou, Marina P Siakantaris, Styliani I Kokoris, Evangelia M Dimitriadou, Christina Kalpadakis, Marina Matzouranis, Loukas Kaklamanis, Panayiotis Panayiotidis, Marie-Christine Kyrtsonis, Athina Androulaki, Efstratios Patsouris, Christos Kittas, Gerassimos A Pangalis

To correlate the immunohistochemical expression of topoisomerase IIalpha (topoIIalpha) in Hodgkin's lymphoma (HL) with clinicopathological parameters, the expression of Ki-67 and the outcome of patients, who had been homogenously treated with ABVD or equivalent regimens. Immunohistochemistry using the monoclonal antibody Ki-S1 (topoIIalpha) was performed in 238 HL patients. MiB1 (Ki-67) expression was evaluated in 211/238. The mean +/- SD percentage of topoIIalpha- and Ki-67-positive Hodgkin-Reed-Sternberg (HRS) cells was 63 +/- 19% (5%-98%) and 73 +/- 19% (8%-99%), respectively. The median percentage of topoIIalpha-positive HRS cells was 64% (interquartile range, 51-78%). There was no correlation between topoIIalpha expression and patient characteristics. TopoIIalpha and Ki-67 expression were correlated (Spearman's Rho 0.255, P < 0.001). TopoIlalpha expression within the highest quartile of this patient population was predictive of failure free survival (FFS) (10-year rates 82 +/- 3% vs 68 +/- 7%, P = 0.02 for patients falling into the quartiles 1-3 and 4 respectively). In multivariate analysis topoIIalpha expression was independently predictive of FFS. TopoIIalpha was expressed in all cases of HL showing a correlation with Ki-67 expression. Under current standard therapy including drugs inhibiting its activity, topoIIalpha was an independent adverse predictor of FFS with no statistically significant correlation with other established prognostic factors.